Application covers seamless portfolio transition from “wet lab” benchtop products through to “dry lab” digital applications The Workflow Configurator allows customers to quickly find the best ...

Three new innovative instrument launches expand reach into further lab segments and sample preparation customers as QIAGEN strengthens market-leading position QIAsymphony Connect set to start phased ...

Key growth drivers include the rising shift towards personalized medicine and the demand for non-invasive diagnostics, particularly in oncology Omics Lab Services Market Omics Lab Services Market ...

QIAGEN N.V. QGEN recently announced that it will offer its premium enzymes as standalone solutions, giving researchers and business clients the freedom to design their own tests and workflows. As a ...

Venlo, the Netherlands, Feb. 15, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced two significant achievements in sustainability through recognitions by My ...

Shares of Qiagen have rebounded after three years following a news report that the provider of biotech workflow solutions was evaluating strategic options, which include a potential sale.

Molecular diagnostics company Qiagen launched the first syndromic test that differentiates between monkeypox and five other viruses with similar symptoms. The QIAstat-Dx Viral Vesicular Panel is ...

In our Case of the Week, the Federal Circuit reversed a jury finding of infringement from the District of Delaware, holding that the jury’s findings and seven-figure damages award were not ...

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample ...

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments during 2025 and 2026 ...